文献速递脑血管病神经重症与神经感染

单中心综合卒中中心6至24小时时间窗血管内试验入组资格分析

Eligibility for Endovascular Trial Enrollment in the 6- to 24-Hour Time Window: Analysis of a Single Comprehensive Stroke Center.
PubMed 文献 · Stroke · 2018-03-16

该回顾性研究分析了单中心综合卒中中心在DAWN试验入组期间(2014年11月至2017年2月)收治的2667例急性缺血性卒中患者,发现30%(n=792)在6至24小时时间窗就诊,其中1.7%符合DAWN试验入组标准,另有0.6%至1%符合DEFUSE-3试验标准,33%的DAWN合格患者不符合DEFUSE-3标准。

要点

  • 2667例急性缺血性卒中患者中,30%(n=792)在6至24小时时间窗就诊,47%(n=1242)NIHSS≥6。
  • 45例符合全部DAWN试验标准,47至58例符合DEFUSE-3试验标准。
  • 33%的DAWN合格患者不符合DEFUSE-3标准。

核心结论

  • 在所有就诊于单中心综合卒中中心的急性缺血性卒中患者中,1.7%符合DAWN临床试验入组资格,另有0.6%至1%符合DEFUSE-3试验资格。
  • 这些数据预测取栓利用率将增加,对综合卒中中心资源优化和卒中诊疗体系具有重要影响。

研究设计与样本

  • 回顾性审查单中心DAWN试验参与综合卒中中心在DAWN入组期间(2014年11月至2017年2月)收治的缺血性卒中患者,以识别符合DAWN和DEFUSE-3入组标准的患者。
  • 对6小时后就诊的患者进一步调查以明确试验排除原因。

主要发现

  • 研究期间收治的2667例急性缺血性卒中患者中,30%(n=792)在6至24小时时间窗就诊,47%(n=1242)NIHSS评分≥6。
  • 基于大血管闭塞、基线改良Rankin量表评分、核心梗死和灌注成像(如有)进一步应用临床试验特异性选择标准。
  • 45例符合全部DAWN试验标准,47至58例符合DEFUSE-3试验标准。
  • 33%的DAWN合格患者不符合DEFUSE-3标准。
  • 在所有急性缺血性卒中患者中,1.7%符合DAWN临床试验入组资格,另有0.6%至1%符合DEFUSE-3试验资格。

关键数值与推荐

  • DAWN试验入组标准:包括大血管闭塞、基线改良Rankin量表评分、核心梗死和灌注成像(如有)等临床试验特异性选择标准。
  • DEFUSE-3试验入组标准:包括大血管闭塞、基线改良Rankin量表评分、核心梗死和灌注成像(如有)等临床试验特异性选择标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The results of the DAWN trial (Diffusion-Weighted Imaging or Computerized Tomography Perfusion Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) support the benefit of endovascular therapy in patients presenting beyond the 6-hour time window with anterior circulation large vessel occlusions. The impact of these results with respect to additional number of eligible patients in clinical practice remains unknown. METHODS: A retrospective review of ischemic stroke admissions to a single DAWN trial-participating comprehensive stroke center was performed during the DAWN enrollment period (November 2014 to February 2017) to identify patients meeting criteria for DAWN and DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke-3) eligibility. Patients presenting beyond 6 hours were further investigated to clarify reasons for trial exclusion. RESULTS: Of the 2667 patients with acute ischemic stroke admitted within the study period, 30% (n=792) presented within the 6- to 24-hour time window, and 47% (n=1242) had a National Institutes of Health Stroke Scale ≥6. Further clinical trial-specific selection criteria were applied based on the presence of large vessel occlusion, baseline modified Rankin Scale score, core infarct, and perfusion imaging (when available). There were 45 patients who met all DAWN trial criteria and 47 to 58 patients who would meet DEFUSE-3 trial criteria. Thirty-three percent of DAWN-eligible patients are DEFUSE-3 ineligible. CONCLUSIONS: Of all patients with acute ischemic stroke presenting to a single comprehensive stroke center, 1.7% of patients qualified for DAWN clinical trial enrollment with an additional 0.6% to 1% qualifying for the DEFUSE-3 trial. These data predict an increase in thrombectomy utilization with important implications for comprehensive stroke center resource optimization and stroke systems of care.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Jadhav AP, Desai SM, Kenmuir CL, et al. Eligibility for Endovascular Trial Enrollment in the 6- to 24-Hour Time Window: Analysis of a Single Comprehensive Stroke Center. Stroke. 2018. PMID: 29581344. doi:10.1161/STROKEAHA.117.020273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。